CTLA4 and lung carcinoma: This is proven by certain biologicals that have recently been established as targeted treatment options for lung cancer, targeting for instance cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) (ipilimumab), or PD-1-receptor and PD-1 ligand (PD-L1) which are targeted by nivolumab and atezolizumab [49].